Loading clinical trials...
Loading clinical trials...
An Open-label, Multi-centre, Phase I/II Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies
Conditions
Interventions
CN1, 0.5mg/kg and CN401, 400mg
CN1, 1mg/kg and CN401, 600mg
+3 more
Locations
1
Australia
Monash Health - Monash Medical Centre
Bentleigh, Victoria, Australia
Start Date
July 28, 2021
Primary Completion Date
August 29, 2022
Completion Date
September 30, 2022
Last Updated
October 24, 2022
Lead Sponsor
Curon Biopharmaceutical (Australia) Co Pty Ltd
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions